Sugi Predict

Sugi Predict / Compounds / SCHEMBL6899596

SCHEMBL6899596

SCHEMBL6899596

CC(F)(F)c1cccc(I)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 1/20 0.37
▸ TAS1R1 Q7RTX1 1/20 0.37
▸ ACHE P22303 2/20 0.36
▸ TSHR P16473 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ PGK1 P00558 1/20 0.33
▸ PGK2 P07205 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ RXRA P19793 1/20 0.33
▸ GRIN1 Q05586 1/20 0.33
▸ GRIN2B Q13224 1/20 0.33
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ IDO1 P14902 1/20 0.32
▸ CES2 O00748 1/20 0.32
▸ MGLL Q99685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30148546 1.00 TAS1R3 (0.37) TAS1R3TAS1R1ACHETSHRMAPK1
SCHEMBL15191919 0.83 PDE2A (0.37) ACHETSHRMAPK1PGK1PGK2
SCHEMBL134474 0.81 HDAC8 (0.47) ACHETSHRESR1ESR2ALDH1A1
SCHEMBL29438862 0.81 TSHR (0.54) TSHRMAPK1ALDH1A1HTR2AHTR2C
SCHEMBL1377 0.81 TSHR (0.54) TSHRMAPK1ALDH1A1HTR2AHTR2C
SCHEMBL26068824 0.79 ACHE (0.36) ACHETSHRMAPK1PGK1PGK2
SCHEMBL26811585 0.79 ESR1 (0.34) MAPK1ESR1ESR2IDO1MGLL
SCHEMBL23240898 0.77 TSHR (0.40) TSHRMAPK1PGK1PGK2ALDH1A1
SCHEMBL18243516 0.77 FAAH (0.39) ACHEESR1ESR2RXRAIDO1
SCHEMBL22619018 0.77 PGK1 (0.38) ACHETSHRMAPK1PGK1PGK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2025-04-10 — — US disclosed
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors GENENTECH, INC. (US) 2025-01-28 — — US disclosed
CN-117580836-A Pyrimidine ring structure derivative and application thereof 四川汇宇制药股份有限公司 2024-02-20 — — CN disclosed
WO-2022268209-A1 DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF 四川汇宇制药股份有限公司 2022-12-29 — — WO disclosed
WO-2022268209-A1 DERIVATIVE HAVING PYRIMIDINE-FUSED CYCLIC STRUCTURE, AND USE THEREOF 四川汇宇制药股份有限公司 2022-12-29 — — WO disclosed
WO-2022146698-A1 SOS1 INHIBITORS AND USES THEREOF Revolution Medicines, Inc. (US) 2022-07-07 — — WO disclosed
US-20220081423-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2022-03-17 — — US disclosed
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS GENENTECH, INC. (US) 2021-07-15 — — US disclosed
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS GENENTECH, INC. (US) 2021-07-15 — — US disclosed
US-11028075-B2 Therapeutic compounds and methods of use thereof GENENTECH, INC. (US) 2021-06-08 — — US disclosed
EP-3797101-A1 PYRIDIDNE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS F. Hoffmann-La Roche AG (CH) 2021-03-31 — — EP disclosed
CN-112368274-A Pyridine-sulfonamide derivatives as sodium channel inhibitors 豪夫迈·罗氏有限公司 2021-02-12 — — CN disclosed
CN-112041313-A Pyridine-sulfonamide compounds and their use against pain and related conditions 基因泰克公司 2020-12-04 — — CN disclosed
US-20190263786-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-08-29 — — US disclosed
EP-2507234-B1 IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2014-03-12 — — EP disclosed
US-8575160-B2 Imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-11-05 — — US disclosed
US-8575160-B2 Imidazole derivatives as aldosterone synthase inhibitors NOVARTIS AG (CH) 2013-11-05 — — US disclosed
US-20130065893-A1 IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2013-03-14 — — US disclosed
US-20130065893-A1 IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2013-03-14 — — US disclosed
WO-2011064376-A1 IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS NOVARTIS AG (CH) 2011-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263786-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF ASAH2, ACER2, PCSK9 TAS1R3 4539/4885TAS1R1 4544/4885ACHE 1702/4885
US-20220081423-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF TRPV1, HCN4, TRPA1 TAS1R3 2400/4885TAS1R1 2865/4885ACHE 460/4885
US-20130065893-A1 IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS CYP11B1, CYP21A2, CYP11B2 TAS1R3 2272/4885TAS1R1 1951/4885ACHE 3093/4885
US-11028075-B2 Therapeutic compounds and methods of use thereof TRPV1, HCN4, TRPA1 TAS1R3 2400/4885TAS1R1 2865/4885ACHE 460/4885
US-12209075-B2 Pyridine-sulfonamide derivatives as sodium channel inhibitors SCN1B, CACNA1A, SCN1A TAS1R3 254/4885TAS1R1 266/4885ACHE 931/4885
US-20210214336-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS SCN1B, CACNA1A, SCN1A TAS1R3 255/4885TAS1R1 263/4885ACHE 874/4885
US-20250115576-A1 THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF F12, REN, ZYX TAS1R3 2698/4885TAS1R1 2258/4885ACHE 2285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.